ISOPAQUE 440
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Nov 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISOPAQUE 440 is an injectable diagnostic agent approved in 1973 by GE HealthCare. The product's specific mechanism of action and therapeutic indications are not disclosed in available data. It is classified as an NDA (New Drug Application) injectable product.
LOE Approaching
With LOE approaching and minimal current commercial data available, the brand team is likely in legacy management or transition planning mode with reduced staffing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, ISOPAQUE 440 represents a legacy portfolio asset offering limited career momentum or growth potential. Career value lies in operational efficiency, relationship management, and transition planning rather than innovation or market expansion.
Medical Science LiaisonField Sales
Worked on ISOPAQUE 440 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.